IDG will present its work at the 13th Annual NIH CAP FeedForward(TM) Sessions. We thank the LARTA Institute for this opportunity and welcome mentor feedback! http://www.larta.org
Read More
IDG will present its work at the 13th Annual NIH CAP FeedForward(TM) Sessions. We thank the LARTA Institute for this opportunity and welcome mentor feedback! http://www.larta.org
Read MoreModern Healthcare: Innovations has featured the Company’s novel approach to pairing the infecting bug with the right drug on the first attempt. Read the full article here: http://www.modernhealthcare.com/article/20170204/MAGAZINE/302049981
Read MoreID Genomics, Inc. has launched a first-of-its-kind initiative uniting clinical partners to fight antibiotic resistance around the world. GenomeWeb covered the news — read more about our efforts here: https://www.genomeweb.com/molecular-diagnostics/id-genomics-launches-consortium-improve-infectious-disease-diagnostics
Read MoreSEATTLE (January 11, 2026) ID Genomics, Inc. announced a national consortium of clinical partners aimed at improving the speed and accuracy of infectious disease diagnosis and antibiotic treatment through the company’s novel DNA-based “bacterial fingerprinting” diagnostics system. The initial consortium was formed under a grant from the National Institutes of Health and includes Group Health Cooperative, Seattle Children’s Research Institute and Harborview Medical Center in Seattle; Los Angeles County Medical Center and
Read MoreID Genomics’ CEO, Dr. Kaveri Parker, will present the Company’s technology and its implications for the American warfighter at the Defense Innovation Challenge in Austin, TX. Please come visit our showcase exhibit at booth 313W in Griffin Hall at the JW Marriott. http://defenseinnovation.us
Read MoreAs the recipient of a $3 million, 3-year Phase II SBIR grant, ID Genomics has been selected for the Commercialization Acceleration Program sponsored by the National Institutes of Health and the Larta Institute. The goal of this program is to assist early stage companies in commercializing their technology by expanding their network to include experts in industry, finance, and regulation. IDG was selected as one of seventy six (76) companies from submissions across the US.
Read MoreID Genomics, Inc. has been selected as an Innovation Challenge company by the Redefining Early Stage Investments (RESI) Conference in Boston, MA. Please come visit our poster and learn more about the conference here: http://www.resiconference.com/resi-boston-2016/
Read MoreIDG is pleased to announce the appointment of Mansour Samadpour, Ph.D. to our Board of Directors. Dr. Samadpour serves as the President and Chief Executive Officer at Molecular Epidemiology, Inc. and Institute for Environmental Health, Inc. Together, these companies form the largest food- and water-safety testing organization in the United States. With 130 ISO certified laboratories in the U.S., Dr. Samadpour has has more than two decades of experience in the successful commercialization of numerous diagnostic products relevant to microbiology,
Read More